# US 2022/0033403 A1 · Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033403 A1
- Document ID: US20220033403A1
- Status: Published application
- Kind: A1
- Application number: 17/230,603
- Filed: 2021-04-14
- Published: 2022-02-03
- Earliest claimed: 2014-12-30
- Assignees: Valo Health, Inc.
- Applicants: Valo Health, Inc.
- Inventors: Stephanos Ioannidis; Adam Charles Talbot; Bruce Follows; Alexandre Joseph Buckmelter; Minghua Wang; Ann-Marie Campbell
- Web page: https://patentgrep.com/patent/US20220033403A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

## Claims

### Claim at position 1

1-47. (canceled)

### Claim 48

A method of treating a disease or disorder associated with modulation of USP7 comprising, administering to a patient in need thereof an effective amount of a compound of formula (Ib):
or a pharmaceutically acceptable salt thereof,
wherein:
X1 is C;
R2 is (C1-C8) alkyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R8;
R4 is H or (C1-C6) alkyl;
R6 is H;
R7 is H, halogen, —NR17C(O)R18 or —NR17C(O)NR18R19;
each R8 is independently (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, CN, —(C0-C4)-alkylene-aryl, —(C0-C4)-alkylene-heteroaryl, (C3-C10) cycloalkyl, heterocycloalkyl, —C(O)R12, —S(O)qR12, —(C0-C3)-alkylene-NR12R13, or —OR12, wherein alkyl, alkylene, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R9;
each R9 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, halogen, CN, —S(O)qR14, —S(O)qNR14R15, —C(O)NR14R15, —NR14C(O)R15, (C6-C14) aryl, heteroaryl, (C3-C8) cycloalkyl, or heterocycloalkyl, wherein alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R10; or
two R9 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R10; or
two R9 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R10; or
two R9 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R10; or
two R9 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R10;
each R10 is independently at each occurrence (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C1-C4) haloalkoxy, halogen, —OH, or CN; or
two R10 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R11; or
two R10 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R11; or
two R10 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R11; or
two R10 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, —NH2, or CN;
each R12 and R13 is independently H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R16;
each R14 and R15 is independently H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R16; or
R14 and R15 together with the nitrogen to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R16, when R9 is —C(O)NR14R15;
each R16 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, or CN;
R17 is independently H or (C1-C6) alkyl;
R18 is independently (C1-C6) alkyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R20;
R19 is independently H or (C1-C6) alkyl;
each R20 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, CN, (C6-C14) aryl, —O(C6-C14) aryl, or heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more R21; or
two R20 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R21; or
two R20 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R21; or
two R20 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R21; or
two R20 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R21;
each R21 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, or CN; and
q is independently at each occurrence 0, 1, or 2.

### Claim 49 (depends on 48)

The method according to claim 48, wherein R4 is H.

### Claim 50 (depends on 49)

The method according to claim 49, wherein R7 is H.

### Claim 51 (depends on 50)

The method according to claim 50, wherein R2 is (C1-C8) alkyl, wherein the alkyl is optionally substituted with one more R8.

### Claim 52 (depends on 51)

The method according to claim 51, wherein R2 is (C1-C8) alkyl, wherein the alkyl is substituted with one more R8.

### Claim 53 (depends on 52)

The method according to claim 52, wherein R2 is (C1-C8) alkyl, wherein the alkyl is substituted with —(C0-C4)-alkylene-aryl.

### Claim 54 (depends on 52)

The method according to claim 52, wherein R2 is (C1-C8) alkyl, wherein the alkyl is substituted with —(C0-C4)-alkylene-heteroaryl.

### Claim 55 (depends on 48)

The method according to claim 48, wherein the compound is (R)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one, or a pharmaceutically acceptable salt thereof.

### Claim 56 (depends on 48)

The method according to claim 48, wherein the compound is 3-((1-(3-(1H-pyrrol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one, or a pharmaceutically acceptable salt thereof.

### Claim 57 (depends on 48)

The method according to claim 48, wherein the disease or disorder associated with modulation of USP7 is cancer and metastasis, neurodegenerative diseases, immunological disorders, diabetes, bone and joint diseases, osteoporosis, arthritis inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, viral infectivity and/or latency, and bacterial infections and diseases.

### Claim 58

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
X1 is C, S, or S(O);
X2 is CR7 or N;
R1 is H, D, —OH, —SH, —NH2, —NH(C1-C4) alkyl, —N((C1-C4) alkyl)2, or F;
R2 is (C1-C8) alkyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, heterocycloalkyl, —NR25R26, or —OR25, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R8;
each R3 is independently at each occurrence selected from D, (C1-C6) alkyl, (C6-C14) aryl, heteroaryl, (C3-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R21; or
two R3 together when on adjacent carbons form a (C3-C8) cycloalkyl optionally substituted with one or more R21; or two R3 together form a (C3-C8) spirocycloalkyl optionally substituted with one or more R21; or two R3 together form a spiroheterocycloalkyl optionally substituted with one or more R21; or two R3 together when on adjacent carbons form an aryl ring optionally substituted with one or more R21; or two R3 together when on adjacent carbons form an heteroaryl ring optionally substituted with one or more R21;
R4 is H, (C1-C6) alkyl, CD3, (C6-C14) aryl, heteroaryl, (C3-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R22;
R5 and R5′ are independently H, D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, —CH2OH, —CH2NH2, or halogen;
R6 is H, D, or (C1-C6) alkyl;
R7 is H, D, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, halogen, —NR17C(O)R18, CN, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, —SF5, —NR17C(O)NR18R19, or —C(O)NR17R18, wherein the alkyl, alkenyl, and alkynyl are optionally substituted with one or more R21;
each R8 is independently D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, —(C1-C3)-alkylene-O(C1-C6) alkyl, —(C0-C4)-alkylene-aryl, —(C0-C4)-alkylene-heteroaryl, (C3-C10) cycloalkyl, heterocycloalkyl, —(C0-C4)-alkylene-O-aryl, 7 of 11 —(C0-C4)-alkylene-O-heteroaryl, —O—(C3-C8)cycloalkyl, —S-heteroaryl, halogen, —CN, —C(O)R12, —CO(O)R12, —C(O)NR12R13, —S(O)qR12, —S(O)qNR12R13, —NR12S(O)qR13, —(C0-C3)-alkylene-NR12R13, —NR12C(O)R13, —NR12C(O)C(O)R13, —NR12C(O)NR12R13, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, —SF5, or —OR12, wherein alkyl, alkylene, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R9;
each R9 is independently at each occurrence D, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C8) cycloalkyl, heterocycloalkyl, (C6-C14) aryl, heteroaryl, halogen, —OH, —CN, —C(O)R14, —C(O)NR14R15, —NR14C(O)R15, —NR14R15, —S(O)qR14, —S(O)qNR14R15, —NR14S(O)qR15, oxo, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, —SF5, —O-aryl, CN, or —O-heteroaryl, wherein alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more R10; or
two R9 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R10; or two R9 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R10; or two R9 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R10; or two R9 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R10;
each R10 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —NR23C(O)R24, —NR23S(O)qR24, —C(O)R23, —C(O)NR23R24, —NR23R24, —S(O)qR23, —S(O)qNR23R24, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, —SF5, —OH, or CN; or
two R10 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R11; or two R10 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R11; or two R10 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R11; or two R10 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R11;
each R11 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, —NH2, or CN;
each R12 and R13 is independently H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R16;
each R14 and R15 is independently H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R16; or
R14 and R15 together with the nitrogen to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R16, when R9 is —C(O)NR14R15;
each R16 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, or CN;
R17 is independently H or (C1-C6) alkyl;
R18 is independently (C1-C6) alkyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R20;
R18 is independently H or (C1-C6) alkyl;
each R20 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, CN, (C6-C14) aryl, —O(C6-C14) aryl, or heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more R21; or
two R20 together with the atoms to which they are attached form a (C6-C14) aryl ring optionally substituted with one or more R21; or two R20 together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R21; or two R20 together with the atoms to which they are attached form a (C5-C8) cycloalkyl ring optionally substituted with one or more R21; or two R20 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R21;
each R21 is independently at each occurrence (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, halogen, —OH, or CN;
each R22 is independently at each occurrence D, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C3-C8) cycloalkyl, (C6-C14) aryl, heteroaryl, —O-aryl, —O-heteroaryl, —O-heterocycloalkyl, —O—(C3-C8)cycloalkyl, —S(O)q(C1-C6) alkyl, —C(O)O(C1-C6) alkyl, —C(O)NR23R24, —S(O)qNR23R24, —NR23R24, —NR23C(O)NR23R24, —NR23C(O)OR24, —NR23S(O)qR23, —NR23C(O)R24, halogen, —P(O)((C1-C6)alkyl)2, —P(O)(aryl)2, —SiMe3, —SF5 or —OH, wherein alkyl, aryl, heteroaryl, heterocycloalkyl, and cycloalkyl are optionally substituted with one or more substituents independently selected from (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, halogen, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, —OH, CN, —NH2, —NH(C1-C4) alkyl, —N((C1-C4) alkyl)2, (C6-C14) aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl are optionally substituted one or more substituents independently selected from (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, halogen, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl —OH, CN, —NH2, —NH(C1-C4) alkyl, or —N((C1-C4) alkyl)2;
each R23 and R24 is independently at each occurrence H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl;
each R25 and R26 is independently H, (C1-C6) alkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C6-C14) aryl, heteroaryl, (C5-C8) cycloalkyl, or heterocycloalkyl, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, halogen, (C1-C6) haloalkoxy, (C1-C6) hydroxyalkyl, —OH, CN, —NH2, —NH(C1-C4) alkyl, or —N((C1-C4) alkyl)2;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, or 3; and
q is independently at each occurrence 0, 1, or 2.

### Claim 59 (depends on 58)

A method of treating a neurodegenerative disease, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 58.

### Claim 60 (depends on 58)

A method of treating a viral infection and disease, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 58.

### Claim 61 (depends on 58)

A method of treating an inflammatory disease or condition, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 58.
